SCHEDULE: Sands Capital Discloses 5.6% Stake in Acumen Pharma

Sands Capital Alternatives and affiliated funds reported a 5.6% beneficial ownership stake in Acumen Pharmaceuticals, Inc. as of June 30, 2025.

Summary

• Sands Capital Alternatives, LLC, Sands Capital Ventures Discovery Fund III, L.P., Sands Capital Global Venture Fund II, L.P., Sands Capital Life Sciences Pulse Fund, LLC, and Frank M. Sands collectively reported beneficial ownership in Acumen Pharmaceuticals, Inc.
• Sands Capital Alternatives, LLC and Frank M. Sands each beneficially own 3,417,075 shares of Acumen Pharmaceuticals, Inc. Common Stock, representing 5.6% of the class.
• Sands Capital Ventures Discovery Fund III, L.P. beneficially owns 1,124,729 shares, representing 1.9% of the class.
• Sands Capital Global Venture Fund II, L.P. beneficially owns 1,146,173 shares, representing 1.9% of the class.
• Sands Capital Life Sciences Pulse Fund, LLC beneficially owns 1,146,173 shares, representing 1.9% of the class.
• The percentages are based on 60,573,425 shares outstanding as of August 8, 2025, as reported in Acumen Pharmaceuticals' Form 10-Q filed on August 12, 2025.
• The reporting persons disclaim beneficial ownership of any securities beyond their pecuniary interest therein.

Sentiment

Score: 6

Explanation: The filing indicates a significant passive investment by Sands Capital, a reputable investment firm, in Acumen Pharmaceuticals. This suggests institutional confidence, which is generally a positive signal for the company's stock, though the filing itself is purely an ownership disclosure.

Positives

• Significant institutional investment from Sands Capital, indicating confidence in Acumen Pharmaceuticals.
• The collective beneficial ownership of 5.6% by Sands Capital Alternatives, LLC and Frank M. Sands represents a notable stake in the company.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Increased institutional ownership may be viewed positively, potentially signaling validation of the company's prospects and attracting further investor interest.

Key Dates

Recommendation

The filing indicates a significant, passive stake by a major institutional investor, Sands Capital. This suggests a long-term interest and confidence in Acumen Pharmaceuticals. While not a direct endorsement of future performance, the presence of such an investor typically provides a level of stability and validation, making a 'hold' recommendation appropriate for existing investors and signaling potential for new investors to consider the stock.

Keywords

Acumen Pharmaceuticals, Sands Capital, Institutional Ownership, SEC Filing, Schedule 13G, Common Stock, Beneficial Ownership, Investment Management, Biotechnology